Literature DB >> 29550740

Factors associated with concurrent heroin use among patients on methadone maintenance treatment in Vietnam: A 24-month retrospective analysis of a nationally representative sample.

Thai Hoang1, Hong Nguyen2, Ray W Shiraishi3, Mai Nguyen4, Trista Bingham3, Diep Nguyen4, Tam Nguyen4, Hao Duong5, Sheryl Lyss2, Hien Tran4.   

Abstract

BACKGROUND: Methadone maintenance treatment (MMT) is highly effective for reducing heroin use and HIV transmission among people who inject opioids. We sought to measure and understand factors associated with continued heroin use, a critical factor affecting treatment outcome among MMT patients in Vietnam.
METHOD: We collected data from medical charts of a nationally representative sample of patients who were on MMT from May 2008 to December 2013. We selected 10 MMT clinics using probability proportional to size and 50 patients/clinic by systematic random sampling. Concurrent heroin use was defined by self-report/positive urine test recorded in patient charts during month 3, 6, 12, and 24 after MMT initiation. We used multivariable logistic regression to identify factors associated with concurrent heroin use over the first 24 months in treatment.
FINDINGS: All clients used heroin at baseline; concurrent heroin use was 55% at month 3; 19%, 14.6% and 15.2% at month 6, 12, and 24, respectively. Having no family emotional/financial support at baseline versus having this support (AOR = 2.03; 95% confidence interval [CI] = 1.17-3.53); using heroin for <15 years versus ≥15 years at baseline (AOR = 1.55; 95% CI = 1.01-2.38); being HIV-infected/not on antiretroviral treatment (ART; AOR = 1.79; 95% CI = 1.07-2.98) or being HIV infected/on ART (AOR = 2.39; 95% CI = 1.61-3.55), versus not being HIV infected; baseline methamphetamine use versus non-use (AOR = 2.68; 95% CI = 1.08-6.65), were associated with increased odds of concurrent heroin use among patients.
CONCLUSION: The association between concurrent heroin use among MMT patients and lack of family emotional/financial support, highlights the critical importance of these types of support for successful treatment. Association with shorter heroin use history suggests motivational enhancement may reduce concurrent heroin use. Living with HIV, whether on ART or not, is associated with increased concurrent heroin use and suggests safe injection commodities and education, and drug-drug interaction management, are needed for this subgroup. Though few MMT clients reported baseline methamphetamine use, its association with later heroin use suggests the need for effective methamphetamine use interventions. Published by Elsevier B.V.

Entities:  

Keywords:  ART; Concurrent heroin use; HIV; Heroin use; Methadone maintenance treatment

Mesh:

Substances:

Year:  2018        PMID: 29550740      PMCID: PMC5981011          DOI: 10.1016/j.drugpo.2018.02.020

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  30 in total

1.  Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment.

Authors:  Anja Dobler-Mikola; Josef Hättenschwiler; Daniel Meili; Thilo Beck; Edi Böni; Jiri Modestin
Journal:  J Subst Abuse Treat       Date:  2005-12

Review 2.  Could low dead-space syringes really reduce HIV transmission to low levels?

Authors:  P Vickerman; N K Martin; M Hickman
Journal:  Int J Drug Policy       Date:  2012-11-30

3.  The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.

Authors:  S M Clarke; F M Mulcahy; J Tjia; H E Reynolds; S E Gibbons; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

4.  Family support, quality of life and concurrent substance use among methadone maintenance therapy clients in China.

Authors:  C Lin; Z Wu; R Detels
Journal:  Public Health       Date:  2011-03-16       Impact factor: 2.427

5.  Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.

Authors:  Peter Lawrinson; Robert Ali; Aumphornpun Buavirat; Sithisat Chiamwongpaet; Sergey Dvoryak; Boguslaw Habrat; Shi Jie; Ratna Mardiati; Azarakhsh Mokri; Jacek Moskalewicz; David Newcombe; Vladimir Poznyak; Emilis Subata; Ambrose Uchtenhagen; Diah S Utami; Robyn Vial; Chengzheng Zhao
Journal:  Addiction       Date:  2008-07-10       Impact factor: 6.526

6.  Illicit Heroin and Methamphetamine Use among Methadone Maintenance Treatment Patients in Dehong Prefecture of Yunnan Province, China.

Authors:  Rongrong Wang; Yingying Ding; Hongling Bai; Song Duan; Runhua Ye; Yuecheng Yang; Jibao Wang; Renhai Tang; Meiyang Gao; Na He
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

7.  Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study.

Authors:  Marcus Baumeister; Marc Vogel; Kenneth M Dürsteler-MacFarland; Urs Gerhard; Johannes Strasser; Marc Walter; Gerhard A Wiesbeck; Sylvie A Petitjean
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-12-04

8.  Impact of blended treatment literacy and psychoeducation on methadone maintenance treatment outcomes in Yunnan, China.

Authors:  Bo Zhang; Thomas Cai; Zhihua Yan; Gitau Mburu; Bangyuan Wang; Liping Yang
Journal:  Harm Reduct J       Date:  2016-02-26

Review 9.  Benefits of peer support groups in the treatment of addiction.

Authors:  Kathlene Tracy; Samantha P Wallace
Journal:  Subst Abuse Rehabil       Date:  2016-09-29

10.  Multilevel predictors of concurrent opioid use during methadone maintenance treatment among drug users with HIV/AIDS.

Authors:  Bach Xuan Tran; Arto Ohinmaa; Steve Mills; Anh Thuy Duong; Long Thanh Nguyen; Philip Jacobs; Stan Houston
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more
  7 in total

1.  Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.

Authors:  Dana Button; Ryan Cook; Caroline King; Tong Thi Khuyen; Lynn Kunkel; Gavin Bart; Dinh Thanh Thuy; Diep Bich Nguyen; Christopher K Blazes; Le Minh Giang; P Todd Korthuis
Journal:  Int J Drug Policy       Date:  2021-11-09

2.  Use of methamphetamine and alcohol among people with opioid use disorder and HIV in Vietnam: a qualitative study.

Authors:  Kim A Hoffman; Le Minh Giang; P Todd Korthuis; Andrew Edsall; Dinh Thanh Thuy; Pham Phuong Mai; Nguyen Thu Hang; Tong Thi Khuyen; Nguyen Thu Trang; Lynn E Kunkel
Journal:  BMC Public Health       Date:  2021-09-22       Impact factor: 4.135

3.  Provider Perspectives on Integration of Substance Use Disorder and HIV Care in Vietnam: A Qualitative Study.

Authors:  Andrew Edsall; Thanh Thuy Thi Dinh; Pham Phuong Mai; Kim Hoffman; Hang T Nguyen; Tong Thi Khuyen; Nguyen Thu Trang; Gavin Bart; Le Minh Giang; P Todd Korthuis
Journal:  J Behav Health Serv Res       Date:  2021-04       Impact factor: 1.505

4.  Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients With Long-Term Opioid Substitution Therapy: The OPAL Study.

Authors:  Marie Grall-Bronnec; Edouard-Jules Laforgue; Gaëlle Challet-Bouju; Jennyfer Cholet; Jean-Benoit Hardouin; Juliette Leboucher; Morgane Guillou-Landréat; Caroline Victorri-Vigneau
Journal:  Front Psychiatry       Date:  2019-10-17       Impact factor: 4.157

5.  Examining common mental health disorders in people living with HIV on methadone maintenance therapy in Hanoi, Vietnam.

Authors:  Anisa Y Mughal; Melissa Ann Stockton; Quynh Bui; Vivian Go; Brian W Pence; Tran Viet Ha; Bradley N Gaynes
Journal:  Harm Reduct J       Date:  2021-04-23

Review 6.  Correlates of methamphetamine use severity among patients receiving methadone maintenance treatment for opioid use disorder in Vietnam.

Authors:  Le Minh Giang; Michael J Li; Chukwuemeka N Okafor; Nguyen Bich Diep; Steven J Shoptaw
Journal:  J Subst Abuse Treat       Date:  2021-05-07

7.  Managing amphetamine use is critical to achieving HIV control.

Authors:  Timothy D Mastro; Christopher Akolo; Steven Shoptaw
Journal:  AIDS       Date:  2020-11-01       Impact factor: 4.632

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.